Dosage & Administration:
patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.
RapilogTM should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because RapilogTM has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal
RapilogTM can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, RapilogTM should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. RapilogTM has been shown to be stable in infusion fluids such as 0.9% sodium chloride.
RapilogTM Pen Cartridge: Each box contains 3 ml glass Cartridge.